In Dec., a new achievement was reached by Virginia Contract Research Organization Co., Ltd. (VCRO). A biotech company, which was assisted by VCRO, was granted a cell therapy product phase I/IIa IND clinical-go for adjuvant immunotherapy from the FDA. The professional, integrated, and local team of VCRO successfully helped customers to achieve the next step of product commercialization.
